Niacin plus simvastatin reduces coronary stenosis progression among patients with metabolic syndrome despite a modest increase in insulin resistance: A subgroup analysis of the HDL-Atherosclerosis treatment study

Journal of Clinical Lipidology

Volumn 1, Issue 3, 2007, Pages 203-210

  Vittone, Francesca ^a   Chait, Alan ^a   Morse, Josh S ^b   Fish, Brian ^a   Brown, B Greg ^b   Zhao, Xue Qiao ^b  

^a Division of Metabolism Endocrinology and Nutrition   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Dyslipidemia; Insulin resistance; Lipid therapy; Metabolic syndrome

Indexed keywords

ANTIOXIDANT; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; NICOTINIC ACID; PLACEBO; SIMVASTATIN;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DIABETES MELLITUS; DIET RESTRICTION; DISEASE COURSE; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HIGH RISK PATIENT; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 34447328718     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2007.05.003     Document Type: Article

References (32)

1. Kahn R., Buse J., Ferrannini E., et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28 (2005) 2289-2304
2. Lakka H.M., Laaksonen D.E., Lakka T.A., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 (2002) 2709-2716
3. Malik S., Wong N.D., Franklin S.S., et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110 (2004) 1245-1250
4. Eberly L.E., Prineas R., Cohen J.D., et al. Metabolic syndrome: risk factor distribution and 18-year mortality in the multiple risk factor intervention trial. Diabetes Care 29 (2006) 123-130
5. Ballantyne C.M., Olsson A.G., Cook T.J., et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 104 (2001) 3046-3051
6. Grundy S.M. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol 81 4A (1998) 18B-25B
7. Ballantyne C.M., Herd J.A., Ferlic L.L., et al. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation 99 (1999) 736-743
8. Robins S.J., Collins D., Wittes J.T., et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 285 (2001) 1585-1591
9. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 102 (2000) 21-27
10. Tenkanen L., Manttari M., and Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study. Circulation 92 (1995) 1779-1785
11. Carr D.B., Utzschneider K.M., Hull R.L., et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 53 (2004) 2087-2094
12. Grundy S.M., Brewer Jr. H.B., Cleeman J.I., et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 24 (2004) e13-e18
13. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37 (1988) 1595-1607
14. Kamanna V.S., and Kashyap M.L. Mechanism of action of niacin on lipoprotein metabolism. Curr Atheroscler Rep 2 (2000) 36-46
15. Tenenbaum A., Fisman E.Z., Motro M., and Adler Y. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. Cardiovasc Diabetol 5 (2006) 20
16. Poynten A.M., Gan S.K., Kriketos A.D., et al. Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content. Metabolism 52 (2003) 699-704
17. Grundy S.M., Vega G.L., McGovern M.E., et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 162 (2002) 1568-1576
18. Elam M.B., Hunninghake D.B., Davis K.B., et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 284 (2000) 1263-1270
19. Zhao X.Q., Morse J.S., Dowdy A.A., et al. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). Am J Cardiol 93 (2004) 307-312
20. Brown B.G., Zhao X.Q., Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345 (2001) 1583-1592
21. Brown B.G., Zhao X.Q., Chait A., et al. Lipid altering or antioxidant vitamins for patients with coronary disease and very low HDL cholesterol?. The HDL-Atherosclerosis Treatment Study Design. Can J Cardiol 14 suppl A (1998) 6A-13A
22. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
23. Robins S.J., Rubins H.B., Faas F.H., et al. Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 26 (2003) 1513-1517
24. Wallace T.M., Levy J.C., and Matthews D.R. Use and abuse of HOMA modeling. Diabetes Care 27 (2004) 1487-1495
25. Carlson L.A. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 258 (2005) 94-114
26. Ito M.K. The metabolic syndrome: pathophysiology, clinical relevance, and use of niacin. Ann Pharmacother 38 (2004) 277-285
27. Alvarsson M., and Grill V. Impact of nicotinic acid treatment on insulin secretion and insulin sensitivity in low and high insulin responders. Scand J Clin Lab Invest 56 (1996) 563-570
28. Kannel W.B., and McGee D.L. Diabetes and cardiovascular disease. The Framingham study. JAMA 241 (1979) 2035-2038
29. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
30. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 9493 (2005) 1267-1278
31. Canner P.L., Furberg C.D., Terrin M.L., et al. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 95 (2005) 254-257
32. Canner P.L., Furberg C.D., and McGovern M.E. Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 97 (2006) 477-479